## Evaluation Tests to Consider - ISO 10993-1:2003\*

Section 6: Selection of biological evaluation tests; Tables 1 / 2

Device Categorized as:			Biological Effects									
<b>B</b> ody <b>C</b> ontact		Contact Duration  Limited •Less than 24 hours  Prolonged •24 hours to 30 days  Permanent •Over 30 days	Cytotoxicity	Sensitization	Irritation or Intracutaneous Reactivity	Systemic Toxicity (acute)	Subacute and Subchronic Toxicity	Genotoxicity	I mplantation	Hemocompatibility	Chronic Toxicity	Carcinogenicity
Surface Device	Skin	Limited	•	•	•							
		Prolonged	<b>*</b>	<b>*</b>	<b>*</b>							
		Permanent	•	<b>*</b>	•							
	Mucosal Membrane	Limited	•	•	<b>*</b>							
		Prolonged	•	•	<b>*</b>							
		Permanent	•	•	<b>*</b>		•	•				
	Breached or compromised surfaces	Limited	•	•	•							
		Prolonged	•	•	•							
		Permanent	•	•	<b>*</b>		•	<b>*</b>				
External communicating device	Blood Path, Indirect	Limited	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>				<b>*</b>		
		Prolonged	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>				<b>*</b>		
		Permanent	<b>*</b>	<b>*</b>		<b>*</b>	<b>*</b>	•		•	<b>*</b>	•
	Tissue/Bone/ Dentin	Limited	•	•	<b>*</b>							
		Prolonged	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>			
		Permanent	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>	•	•		•	•
	Circulating Blood	Limited	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>				<b>*</b>		
		Prolonged	•	•	<b>*</b>	<b>♦</b>	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>		
		Permanent	<b>*</b>	<b>*</b>	<b>*</b>	<b>♦</b>	<b>*</b>	<b>*</b>	<b>*</b>	•	<b>*</b>	*
Implant device	Tissue/Bone	Limited	•	•	•							
		Prolonged	•	•	•	<b>♦</b>	<b>*</b>	<b>*</b>	<b>*</b>			
		Permanent	•	<b>*</b>	•	•	<b>*</b>	<b>*</b>	<b>*</b>			
	Blood	Limited	•	•	<b>*</b>	<b>*</b>	<b>*</b>		•	•	•	
		Prolonged	•	•	+	<b>*</b>	<b>*</b>	•	•	•	•	
		Permanent	•	•	•	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>	<b>*</b>

<sup>\*</sup>Additional tests may be required to satisfy FDA requirements.